FCER1A / FcERI Protein (His Tag)

Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide Protein Datasheet

FCER1A / FcERI Protein Product Information

• Synonym: FCER1A, FCE1A
• Protein Construction: A DNA sequence encoding the human FCER1A (P12319) (Met1-Gln205) was expressed with a polyhistidine tag at the C-terminus.
• Source: Human
• Expression Host: Human Cells

FCER1A / FcERI Protein QC Testing

• Purity: > 95% as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Val 26
• Molecular Mass: The recombinant human FCER1A consists of 191 amino acids and predicts a molecular mass of 24.5 KDa. It migrates as an approximately 42-48 KDa band in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH 7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: FCER1A / FcERI protein

FCER1A / FcERI Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

FCER1A / FcERI Protein Description

FcERI, also known as FCER1A, is the alpha subunit of the immunoglobulin epsilon receptor (IgE receptor). IgE receptor is comprised of an alpha subunit(FcERI), a beta subunit, and two gamma subunits. IgE receptor is the initiator of the allergic response. When two or more high-affinity IgE receptors are brought together by allergen-bound IgE molecules, mediators such as histamine that are responsible for allergy symptoms are released. FcERI is glycosylated. It contains 2 Ig-like (immunoglobulin-like) domains.

References

1. Shikanai T. et al., 2002, J Appl Physiol. 93 (1): 37-41.
2. Sada K. et al., 2002, Blood. 100 (6): 2138-44.
3. Takahashi K. et al., 2003, Mol Immunol. 38 (16-18): 1193-9.